Skip to main content
. Author manuscript; available in PMC: 2012 Jul 23.
Published in final edited form as: Cochrane Database Syst Rev. 2011 Jul 6;(7):CD008305. doi: 10.1002/14651858.CD008305.pub2

Appendix 13. Adverse events (1) part 3.

Character-
istic		 Quan SL, 2008 Tian X, 2007 Wang DG 2003 Wang WH, 2006 Wang XL, 2004 Xu CB, 2000 Xu SG, 2002 Zhang G, 2005
Interven-
tion(s) &
control(s)		 I:
Xuezhikang
C:
simvastatin		 I:
Xiaozhiling
(herb
mixture)
C:
simvastatin		 I:
Xuezhikang
C:
pravastatin		 I:
Xuezhikang
C: atorvas-
tatin		 I:
Xuezhikang
C:
simvastatin		 I:
Xuezhikang
C:
pravastatin		 I:
Xuezhikang
C: lovastatin		 I:
Xuezhikang
C: atorvas-
tatin
Deceased
partici-
pants [n]		 I: 0
C: 0
Total: 0		 I: 0
C: 0
Total: 0		 I: ./.
C: ./.
Total: ./.		 I: 0
C: 0
Total: 0		 I: 0
C: 0
Total: 0		 I: 0
C: 0
Total: 0		 I: 0
C: 0
Total: 0		 I: 0
C: 0
Total: 0
Ad-
verse events
[n / %]		 I: 3.6%(2/
56)
C: 6.5%(3/
46)
Total: 4.9%
(5/102)		 I: 8.3%(3/
36)
C: 0 Total: 4.4%
(3/68)		 I: ./.
C: ./.
Total: ./.		 I: 0
C: 6.8%(5/
74)
Total: 3.5%
(5/142)		 I: 0
C: 0
Total: 0		 I: 2.5%(3/
119)
C: 17.2%
Total: ./.		 I: 5.9%(2/
34)
C: 11.8%(4/
34)
Total: 8.8%
(6/68)		 I: 10%(3/
30)
C: 10%(3/
30)
Total: 10%
(6/60)
Serious ad-
verse events [n / %]		 I: 0
C: 0
Total: 0		 I: 0
C: 0
Total: 0		 I: ./.
C: ./.
Total: ./.		 I: 0
C: 0
Total: 0		 I: 0
C: 0
Total: 0		 I: 0
C: 0
Total: 0		 I: 0
C: 0
Total: 0		 I: 0
C: 0
Total: 0
Drop-outs
due to ad-
verse events
[n / %]		 I: 0
C: 0
Total: 0		 I: 0
C: 0
Total: 0		 I: ./.
C: ./.
Total: ./.		 I: 0
C: 0
Total: 0		 I: 0
C: 0
Total: 0		 I: 0
C: 0
Total: 0		 I: 0
C: 1
Total: 1		 I: 0
C: 0
Total: 0
Hospital-
isation [n /
%]		 I: 100%
C: 100%
Total: 100%		 I: 0
C: 0
Total: 0		 I: 0
C: 0
Total: 0		 I: 100%
C: 100%
Total: 100%		 I: ./.
C: ./.
Total: ./.		 I: ./.
C: ./.
Total: ./.		 I: 0
C: 0
Total: 0		 I: ./.
C: ./.
Total: ./.
Out-pa-
tient treat-
ment [n /
%]		 I: 0
C: 0
Total: 0		 I: 100%
C: 100%
Total: 100%		 I: 100%
C: 100%
Total: 100%		 I: 0
C: 0
Total: 0		 I: ./.
C: ./.
Total: ./.		 I: ./.
C: ./.
Total: ./.		 I: 100%
C: 100%
Total: 100%		 I: ./.
C: ./.
Total: ./.
Symptoms [n / %] I: mild
symptoms
(2 cases)
C: nausea
and anorexia
(3 cases)
Total : mild
symptoms
(2 cases)
, nausea and
anorexia (3
cases)		 I: gastroin-
testinal
symptoms
and mild di-
arrhea (3
cases)
C:No
Total: gas-
trointestinal
symptoms
and mild diarrhea
(3
cases)		 I: ./.
C: ./.
Total: ./.		 I: NO
C: GOT, GPT
increased
(3 cases), ab-
dominal dis-
tention(2
cases)
Total: GOT,
GPT
increased
(3 cases), ab-
dominal dis-
tention(2
cases)		 I: NO
C: NO
Total: NO		 I: ab-
dominal dis-
tention and
constipation
(2 patients)
and rash 1
patient)
C: abdom-
inal disten-
tion(7.5%),
constipation
(4.3%)
, nausea and
tiredness
(3.2%), in-
somnia
(2.2%)
Total: ./.		 I: slightly in-
creased
SGPT
(1 case), ab-
dominal dis-
tention (1
case)
C: slightly
increased
SGPT (2
case)
, slightly in-
creased CPK
(1 case)
, pruritus (1
case)
To-
tal: slightly
increased
SGPT
(3 case), ab-
dominal dis-
ten-
tion (1 case)
, slightly in-
creased CPK
(1 case)
, pruritus (1
case)		 I: ab-
dominal dis-
tention (2
cases), stom-
achache (1
patient)
C: ALT in-
creased(1
patient)
, anorexia(2
patients)
Total: ab-
dominal dis-
tention (2
cases), stom-
achache (1
pa-tient), ALT
increased(1
patient)
, anorexia(2
patients)

Footnotes

./.: not reported

C: control; I: intervention; NO: not observed